Oncology | Phase I/ Phase II Developments | FRANCE

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Sanofi to Showcase Oncology Portfolio and Innovative Pipeline at ASCO20 Virtual Scientific Program

Lead Product(s): SAR439859,Palbociclib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

Company going to present clinical data on its oncology portfolio including data on its Phase 1/2 study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

Enterome

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline

Lead Product(s): EO2401

Therapeutic Area: Oncology Product Name: EO2401

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Symbiosis Pharmaceutical Services LTD

Deal Size: $52.6 Million Upfront Cash: Undisclosed

Deal Type: Financing June 25, 2020

Details:

Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Onxeo Announces Approval of the REVocan Study by Regulatory Authorities

Lead Product(s): AsiDNA,Niraparib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer.

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi

Lead Product(s): AsiDNA,Niraparib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

Preclinical data supports the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis

Lead Product(s): Hafnium dioxide,Cisplatin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2020

Details:

The Company remains in position to deliver data from its priority pathways in head and neck cancer and immuno-oncology (I/O) on schedule.

Abivax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma

Lead Product(s): ABX196,Nivolumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

First patient dosed with ABX196, an iNKT (invariant Natural Killer T cell) agonist, in combination with nivolumab.

Transgene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

First Patient Dosed With Artery Infusion of Transgene’s Oncolytic Virus TG6002 for Colorectal Cancer With Liver Metastases

Lead Product(s): TG6002

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

The Phase 1/2a trial evaluates a novel route of administration for TG6002.

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer

Lead Product(s): AsiDNA,Niraparib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

The REVOCAN ph 1b/2 study, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer.

PDC line Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

PDC*line Pharma Raises €20 Million in Series B Financing Round

Lead Product(s): PDC lung01

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Korean Investment Partners

Deal Size: $22.2 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 22, 2020

Details:

Funding will support company’s phase I/II trial with PDC*lung01 candidate in lung cancer.

Find

Find Oncology Drugs in Phase I/II Clinical Development in FRANCE

France

Product Type

Companies

Sanofi

Sanofi to Showcase Oncology Portfolio and Innovative Pipeline at ASCO20 Virtual Scientific Program

Enterome

Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline

Onxeo

Onxeo Announces Approval of the REVocan Study by Regulatory Authorities

Onxeo

Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi

Nanobiotix

NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis

Abivax

Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma

Transgene

First Patient Dosed With Artery Infusion of Transgene’s Oncolytic Virus TG6002 for Colorectal Cancer With Liver Metastases

Onxeo

Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer

PDC line Pharma

PDC*line Pharma Raises €20 Million in Series B Financing Round